It has a market capitalization of US$31m, which means it wouldn’t have the attention of many institutional investors. Stocks Analysis by Modest Money covering: Antares Pharma Inc, Lipocine Inc, Aytu BioScience Inc. An institutional investor recently bought a new position in Aytu Bioscience stock. 10% of the company's shares. AYTU Stock Message Board: An institutional investor is buying 9 million share. , Armistice Capital, Llc, Vanguard Group Inc,. They represent some of the most successful hedge funds in the world. 71% while institutional investors hold 47. Daily Mail and General Trust holds more than 49 percent of Euromoney, which provides business-to-business information. 4 thousand shares of Aytu BioScience Inc. Matt has 7 jobs listed on their profile. On March 10, 2020, Aytu BioScience, Inc. Aytu Bioscience, Inc. That is how Sabby Capital LLC now has an increase position in AYTU by 55,337. KL: SUPERCOMNET TECHNOLOGIES BHD. (NASDAQ:MHLD) by 23. (AYTU), with 1. Welcome! Log into your account. AYTU is producing tangible results with real, revenue-generating products. CGC - key executives, insider trading, ownership, revenue and average growth rates. 24% while institutional investors hold 12. (NASDAQ:AYTU) has 26 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. Steve is a highly respected investor and founder of. Thank you for your interest in W. Clarity Wealth Advisors LLC bought a new stake in Diversified Return International Equity ETF (NYSEARCA:JPIN) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. Aytu BioScience with ticker code (AYTU) now have 2 analysts covering the stock. 1109ERM Euromoney Institutional Investor PLC UK (LSE) GBP GBX 1 1 10000 100% 10:05:00 - 18:30:00 1605AYTU Aytu BioScience Inc US (NASDAQ) USD 1 1 10000 100% 16:35. 55M with Short Float at 12. Here is a quick look at four such penny stocks. 's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time. Seanergy Maritime (SHIP)'s direct offering of $6. The mentioned changes placed institutional holdings at 8,512,340 shares, according to the latest SEC report filing. AYTU : Get atock charts, earnings data, Benzinga ratings and intraday stock tips from independent traders who track AYTU. 5 million common stock purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor. Aytu Bioscience shares last traded at $1. Aytu BioScience, Inc. 15 per share, in a registered direct offering priced at-the-market under Nasdaq rules. 0001, and the exercise price of each Pre-Funded Warrant will equal $0. 49% in the first quarter, owning 6 million shares of AYTU stocks, with the value of $9 million after the purchase of an additional. 73% of the company’s shares. 53 respectively. 42% of the company's stock. AYTU Stock Message Board: An institutional investor is buying 9 million share. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with an institutional investor (the "Purchaser"), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 4,450,000 shares of the Company's common. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the purchase and sale of 7,826,087 shares of Aytu’s common stock (or. Positions in Aytu BioScience Inc. , Ethernity Networks Limited, Firm Capital American Realty Partners Corp, Gaylin Holdings Ltd, PCM Inc, Retail Estates SICAFI SA, Spok Holdings Inc , The Lebanese Company for the Development and Reconstruction of Beirut Central District (A), Yongmao. Company invites individual and institutional investors to attend interactive real-time virtual VirtualInvestorConferences. 5% of Webster Bank N. Crazy moves in AYTU today. ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. AYTU Stock Message Board: An institutional investor is buying 9 million share. 80% of the company’s stock. (NASDAQ:AYTU) over the last session is 7. 37 percent to ratify at $0. The owner of Britain's Daily Mail newspaper plans to return all of its shares in Euromoney Institutional Investor and 200 million pounds cash to eligible shareholders, it said on Sunday. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) — Block & Leviton LLP (www. 55M with Short Float at 12. 10% of the company's shares. ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. The company recorded loss per share of 1. Target pricing at which a trader projects that a buyer will buy a product. 's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time. Diversified Return International Equity ETF accounts for about 0. A sum of 15831692 shares traded at recent session and its average exchanging volume remained at 16. (AYTU), with 1. 70% of the company’s stock. 73% of the company’s shares. AYTU has attracted considerable attention from traders and investors, a scenario that has seen its volume drop -40. The IPO fund raising was widely supported by the Australian public, a large resources-focused institutional investor and the agricultural community which sees a need to address Australia’s reliance on imported potassium fertilisers, necessary for agricultural production. In another most recent transaction, which held on 3/31/2020, SIGMA PLANNING CORP. It appears that more than several institutional investors and hedge funds decided to increase stakes in AYTU in the recent period. 37 percent to ratify at $0. This prospectus supplement also relates to the offering of common stock issuable upon exercise of such Warrants. A number of equities analysts recently weighed in on the stock. ENGLEWOOD, Colo. HONG KONG, Jan 7, 2020 - (ACN Newswire) - Institutional Capital Advisory (Asia) Limited ("ICA"), a leading Asia-based capital markets advisory firm, announced today eight key corporate acces. Zacks Investment Research raised […]. 4 thousand shares of Aytu BioScience Inc. 31, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with an institutional investor (the "Purchaser"), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 4,450,000 shares of the Company's common stock (the. The Company's 9% convertible unsecured subordinated debentures (the "Debentures") issued to an institutional investor in the principal amount of $15 million mature on March 27, 2020. A sum of 15831692 shares traded at recent session and its average exchanging volume remained at 16. In January Ritter Pharmaceuticals announced a reverse merger agreement in which Ritter will change its name to Qualigen, Inc. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. 24% while institutional investors hold 12. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. Pursuant to the Aytu Purchase Agreement, Aytu assumed sales returns of the Pediatric Portfolio made after the closing date of November 1, 2019 and primarily relating to sales prior to November 1, 2019 only to the extent such post-Closing sales returns exceed $2. 44M shares held by insiders accounting for 6. Now you can follow the best of them with one click! Sell-side analysts work for a brokerage firm and evaluate companies based on various investment criteria typically recommending to Buy, Sell, or Hold a stock. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. Virtu Financial LLC owned 0. Aytu Bioscience Inc (NASDAQ:AYTU) shares gapped up before the market opened on Tuesday. which are valued at $50,493. AYTUZ AYTU TRLPF ASPCF. Its P/Cash is valued at 15. Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund focused. 24 institutions hold shares in Aytu BioScience Inc. Following that, we were successful in attracting two reputable Wall Street healthcare analysts from Ladenburg Thallman and Northland Securities. Crazy moves in AYTU today. Aytu Bioscience's stock is owned by a variety of retail and institutional investors. The mentioned changes placed institutional holdings at 8,459,521 shares, according to the latest SEC report filing. What are institutional investors and what other kinds of investors are there. (AYTU), with 1. Aytu BioScience Inc. The gross proceeds to Aytu from this offering are expected to be approximately $9. Aytu BioScience Investigated for Possible Securities Laws Violations; Investors Who Lost Money Should Contact Block & Leviton. 60% of ProPetro Holding Corp. 3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. Aytu Bioscience Inc (NASDAQ:AYTU)’s stock price gapped up before the market opened on Thursday. About Aytu Bioscience (NASDAQ. Aytu BioScience, Inc. (OTCQX: AYTU) ("Aytu"), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced today that it has entered into a $10. Aytu BioScience with ticker code (AYTU) now have 2 analysts covering the stock. It appears that more than several institutional investors and hedge funds decided to increase stakes in AYTU in the recent period. In addition to Finland, where Icebreaker claims to be the most active institutional investor by number of deals, the. 49% in the first quarter, owning 6 million shares of AYTU stocks, with the value of $9 million after the purchase of an additional. (AYTU) and certain of its officers for potential securities fraud. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 13 institutional holders increased their position in Aytu BioScience Inc. Contact for Investors: James Carbonara. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. Institutional Holders Financial Statements. 36M, and float is at 54. Add to My Stocks. For AYTU investors, management has guided toward an achievable goal, which is to place an estimated 200 MiOXSYS® systems worldwide by the end of 2020. See more of Financial Buzz on Facebook. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the purchase and sale of 7,826,087 shares of Aytu's common stock. This prospectus supplement also relates to the offering of common stock issuable upon exercise of such Warrants. Aytu BioScience, Inc. 73% of the company’s shares. Hayden IR (646)-755-7412 SOURCE: Aytu BioScience, Inc. Headquartered in Chicago with an office in London, the firm has more than 150-employees and approximately $24. 34, with a volume of 5,954,324 shares traded. 49% in the first quarter, owning 6 million shares of AYTU stocks, with the value of $9 million after the purchase of an additional. TMX operates global markets, and builds digital communities and analytic solutions that facilitate the funding, growth and success of businesses, traders and investors. Aytu BioScience, Inc. ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. In the most recent purchasing and selling session, KemPharm Inc. (NASDAQ:MHLD) by 23. Institutional investors Altium Capital and Armistice Capital jointly participated in the financing. 3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. biggest challenges facing their. PERTH: Trigg Mining Limited has completed a $4. Aytu is a specialty pharmaceutical company focused on global commercialization of products addressing a variety of medical needs. Clients of the firm include a global institutional investor base domiciled in North America, Europe and Asia. Market Exclusive Sitemap. The purpose of this merger is to focus on development of Qualigen’s nanotechnology therapies for the treatment of cancer and infectious diseases. One of the penny stocks to consider at this point is that of Aytu BioScience (AYTU Free Report), which has made significant gains this week. Aytu is a specialty pharmaceutical company focused on global commercialization of products addressing. 9% while the SPDR Health Care Select Sector ETF was down 3. Clarity Wealth Advisors LLC bought a new stake in Diversified Return International Equity ETF (NYSEARCA:JPIN) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. On March 10, 2020, Aytu BioScience, Inc. ValuEngine upgraded shares of Aytu Bioscience (NASDAQ:AYTU) from a hold rating to a buy rating in a research report sent to investors on Monday morning, ValuEngine reports. 56, with a volume of 9,828,269 shares traded. 00 price objective for the company in a report on Wednesday, […]. 80% of the company’s stock. Positions in Aytu BioScience Inc. 4 thousand shares of Aytu BioScience Inc. The daily trading volume for Aytu BioScience Inc. Real-time streaming quotes of the NASDAQ Composite index components. 97 percent to ratify at $9. (NASDAQ: AYTU) and certain. Separately, Zacks Investment Research raised Aytu Bioscience from a “hold” rating to a “buy” rating and set a $1. Aytu Bioscience (NASDAQ:AYTU) was upgraded by equities researchers at ValuEngine from a "hold" rating to a "buy" rating in a report issued on Monday, ValuEngine reports. 8 billion in assets under management. Armistice was the winner of 2017 US Hedge Fund Performance Awards by HFM for long/short equity, long/short equity long-term performance (5 years) under $1bn, and single manager. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy). 18 Active Energy Group PLC, Castleton Technology PLC, Columbus McKinnon, Emblaze Ltd. An institutional investor recently bought a new position in Aytu Bioscience stock. AYTU institutional investor trades - Aytu BioScience : a breakdown of the latest and past guru buys and sells in the stock. bought approximately 15. Credit Card is NOT required. The exercise price of each Warrant will equal $1. 07% compared to the previous one. The institutional investor owned 278,182 shares of the insurance provider's stock after acquiring an additional 52,200 shares during the period. The securities will be offered only to institutional accredited investors in accordance with Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. Zacks Investment […]. In another most recent transaction, which held on 3/31/2020, SIGMA PLANNING CORP. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) — Block & Leviton LLP (www. 24% while institutional investors hold 12. Securities products and services offered to self-directed investors through ST Invest, LLC. On March 10, 2020, Aytu reported that it reached a license agreement for the exclusive distribution of a point-of-care rapid test for certain COVID-19 antibodies in the U. Aytu BioScience is pursuing an emergency use authorization with the FDA for the COVID-19 IgG/IgM test. (AYTU) Top Institutional Holders. Call participants:. 44M shares held by insiders accounting for 6. Aytu Bioscience shares last traded at $1. 55M with Short Float at 12. In the chart below, we can see that institutions don't own many shares in the company. Whether investors gauge the momentum by recognizing the spike in product sales or by the growth in new prescribers, AYTU is proving their ability to drive adoption of Natesto® at an accelerated. Currently, the Company has one well-known institutional investor (from most recent SEC filing) which is Armistice Capital. On October 11, 2019, Aytu BioScience, Inc. The Nasdaq Biotechnology index was dropping 4. Aytu BioScience (NASDAQ:AYTU) inks agreements with several institutional investors for the direct sale of 16M common shares and one-year warrants to purchase up to 16M common shares at $1. 0 Million Registered Direct Offering Priced At-the-Market today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional. The stock had previously closed at $1. (NASDAQ:AYTU) has 26 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). As of now, AYTU has a P/S, P/E and P/B values of 10. Aytu Bioscience, Inc. boosted its holdings in Aytu Bioscience Inc (NASDAQ:AYTU) by 9. 60% of ProPetro Holding Corp. The shares outstanding are 60. 07% compared to the previous one. (AYTU), with 1. Aytu Bioscience (NASDAQ:AYTU) was upgraded by equities researchers at ValuEngine from a "hold" rating to a "buy" rating in a report issued on Monday, ValuEngine reports. Retail investors can apply in the retail or non-institutional investor category from Nov 8, 2017 to Nov 10, 2017. Aytu BioScience, Inc. 19 this now indicates there is a potential upside of 215. Aytu and Innovus Shareholder Meetings to Approve Merger Scheduled for February 13, 2020. Aytu Bioscience Inc (NASDAQ:AYTU)’s stock price gapped up before the market opened on Thursday. 55M with Short Float at 12. bought approximately 15. (NASDAQ: AYTU) in a $12 million public offering of Class A Units, comprising common stock and warrants and Class B Units comprising Series B Preferred Stock and Warrants. com Newswire) Coronavirus / Pharma (COVID-19) Stock News Bites: Aytu BioScience, Inc. (NASDAQ: AYTU) and certain of its. 77M, and float is at 56. 38% of Nektar Therapeutics worth $14,530,000 as of its most recent SEC filing. 08%), BlackRock Inc. The Company is in negotiations with the debenture holder and its secured lenders with respect to the Debentures. 24% while institutional investors hold 12. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the purchase and sale of 7,826,087 shares of Aytu's common stock. The total Institutional investors and hedge funds own 14. Following these latest developments, around 1. The aggregate market value of the registrant’s common stock, $0. (AYTU), with 1. (NYSE:CAT) by 0. 01 Entry into a Material Definitive Agreement. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www. Aytu BioScience, Inc. Now with the previous closing price of 1. A total of 19,520,000. Access the replay by calling 1-877-481-4010 (toll-free) and using the replay access code 57940. The Charles Schwab Corporation provides a full range of brokerage, banking and financial advisory services through its operating subsidiaries. Following that, we were successful in attracting two reputable Wall Street healthcare analysts from Ladenburg Thallman and Northland Securities. Investing in securities products involves risk, including possible loss of principal. That is how Sabby Capital LLC now has an increase position in AYTU by 55,337. Virtu Financial LLC bought a new stake in Aytu Bioscience Inc (NASDAQ:AYTU) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). TMX operates global markets, and builds digital communities and analytic solutions that facilitate the funding, growth and success of businesses, traders and investors. (NASDAQ: AYTU) and certain of its. 62M shares held by insiders accounting for 15. Investor Alerts Year All Years 2020 2019 2018 2017 2016 2015 2014 2013 2012 Category All Categories 4Web Medical Acerus Pharmaceuticals Aimmune Therapeutics Biolase DxTerity Diagnostics Enteris Biopharma Eton Pharmaceuticals Keystone Dental Misonix/Solsys Medical SWK Holdings Tenex Health Veru Keywords Go. A number of research analysts have recently issued reports on AYTU shares. Each institutional investor who enters into the securities purchase agreement will also enter into a Leak-Out Agreement with the Company (each, a “Leak-Out Agreement” and collectively, the “Leak-Out Agreements”) wherein each investor who is party to a Leak-Out Agreement (together with certain of its affiliates) will agree to not sell. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support. (), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of an aggregate 12,539,187 shares of Aytu's common stock and. Separately, Zacks Investment Research raised Aytu Bioscience from a "hold" rating to a "buy" rating and set a $1. A number of equities analysts recently weighed in on the stock. Great, thank you. 1109ERM Euromoney Institutional Investor PLC UK (LSE) GBP GBX 1 1 10000 100% 10:05:00 - 18:30:00 1605AYTU Aytu BioScience Inc US (NASDAQ) USD 1 1 10000 100% 16:35. 27 institutions hold shares in Aytu BioScience Inc. For AYTU investors, management has guided toward an achievable goal, which is to place an estimated 200 MiOXSYS® systems worldwide by the end of 2020. In addition, the Company is also in active discussions with Aytu Biosciences (AYTU), a marketer of a COVID-19 IgG/IgM Rapid Test, and Henry Schein Medical (HSIC), the developer of the Standard Q COVID-19 test, to deploy their respective rapid antibody blood testing solutions. ENGLEWOOD, Colo. (AYTU), with 1. If you have additional questions, please call Investor Relations on 212-492- 1110. [NASDAQ:AYTU] by around 2,900,218 shares. A company's changing earnings picture is at the core of the Zacks rating. A total of 19,520,000. An upward trend in earnings estimates -- one of the most powerful. [NASDAQ:AYTU] by around 2,945,240 shares. In the chart below, we can see that institutions don't own many shares in the company. 73% of the company’s shares. 42% of the stock is owned by institutional investors. 17th Annual Institutional Investor Conference. Institutional investors Altium Capital and Armistice Capital jointly participated in the financing. The stock had previously closed at $1. In certain circumstances, securities with respect to which the relevant exchange has commenced delisting proceedings may continue to be traded pending appeal of that determination. The range between the high target price and low target price is between 5 and 2. The shares outstanding are 56. The Company is in negotiations with the debenture holder and its secured lenders with respect to the Debentures. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. Morning Brief: Marcato Liquidates Deckers Stake The activist hedge fund manager has sold its shares in the UGG maker after losing its proxy fight last year. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. 01 Entry into a Material Definitive Agreement. 55M with Short Float at 12. Now you can follow the best of them with one click! Sell-side analysts work for a brokerage firm and evaluate companies based on various investment criteria typically recommending to Buy, Sell, or Hold a stock. 80% of the company’s stock. 25 and (ii) warrants to. 03%) and HCR Wealth Advisors (0. An institutional investor recently bought a new position in Aytu Bioscience stock. Clarity Wealth Advisors LLC bought a new stake in Diversified Return International Equity ETF (NYSEARCA:JPIN) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. Positions in Aytu BioScience Inc. Aytu Bioscience shares last traded at $1. The shares outstanding are 60. 04 million shares. See why Aytu BioScience (AYTU) investor sentiment is more positive in comparison to other stocks in the Services sector. The institutional investor owned 278,182 shares of the insurance provider's stock after acquiring an additional 52,200 shares during the period. (AYTU)’s share price increased by 3. In the chart below below, we can see that institutions don’t own many shares in the company. 44M shares held by insiders accounting for 6. , July 28, 2016 /PRNewswire/ -- Aytu BioScience, Inc. your username. 0 Million Registered Direct Offering Priced At-the-Market today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional. 's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time. On March 10, 2020, Aytu BioScience, Inc. stock-index futures pointed to a slight pullback for Thursday after strong gains in regular trade Wednesday, as investors braced for an updated report. (NASDAQ: AYTU) and certain of its. (NASDAQ:AYTU) over the last session is 7. institutional ownership is held at 20. Aytu BioScience with ticker code (AYTU) now have 2 analysts covering the stock. , or a similar name selected by Qualigen. 49% in the first quarter, owning 6 million shares of AYTU stocks, with the value of $9 million after the purchase of an additional. Aytu Bioscience, Inc. That is how Sabby Capital LLC now has an increase position in AYTU by 55,337. 25% of the company’s shares. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www. SOHM manufacturing and marketing target the rapidly growing healthcare segments such as Nutraceuticals, Cosmeceuticals,. (-) Aytu BioScience (AYTU) slumped Wednesday, dropping over 34% and reversing a nearly 20% advance for the specialty drugmaker that followed the company earlier announcing a $9 million at-the-market direct offering of more than 7. Shares of Aytu Bioscience Inc (NASDAQ:AYTU) gapped down before the market opened on Wednesday. TransCanada Co. Clients of the firm include a global institutional investor base domiciled in North America, Europe and Asia. Gary knows a lot about what went down with the big banks during and after. (AYTU) Top Institutional Holders. In the most recent purchasing and selling session, KemPharm Inc. your username. AYTU investors were disappointed as the stock returned -30. The institutional investor bought 6. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) — Block & Leviton LLP (www. Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund focused. The shares outstanding are 60. Aytu Announces $9. stocks are owned by institutional investors and hedge funds. Aytu BioScience, Inc. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. Good luck, everyone~! Edit - Regarding the SEC Form 4 submitted, it was NOT for an AYTU. 59M, and float is at 54. Its banking subsidiary, Charles Schwab Bank (member. HK: CK Hutchison Holdings Ltd. AYTU has attracted considerable attention from traders and investors, a scenario that has seen its volume drop -71. About Aytu Bioscience. Aytu BioScience Inc. KL: SUPERCOMNET TECHNOLOGIES BHD. ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. 00 price objective for the company in a report on Wednesday, […]. 55M with Short Float at 12. 18 percent to ratify at $1. Credit Suisse AG owned about 0. It appears that more than several institutional investors and hedge funds decided to increase stakes in AYTU in the recent period. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the purchase and sale of 7,826,087 shares of Aytu's common stock (or. Founder and CIO of healthcare institutional investor Armistice Capital. ENGLEWOOD, CO / ACCESSWIRE / March 19, 2020 / Aytu BioScience, Inc. Which institutional investors are buying and selling shares of Aytu Bioscience (NASDAQ:AYTU) stock? View the most recent institutional ownership activity and 13F transactions for AYTU stock at MarketBeat. Investor Alerts Year All Years 2020 2019 2018 2017 2016 2015 2014 2013 2012 Category All Categories 4Web Medical Acerus Pharmaceuticals Aimmune Therapeutics Biolase DxTerity Diagnostics Enteris Biopharma Eton Pharmaceuticals Keystone Dental Misonix/Solsys Medical SWK Holdings Tenex Health Veru Keywords Go. Zacks Investment […]. The company recorded loss per share of 1. Among health care stocks moving on news, Aytu BioScience (AYTU) slumped Wednesday, dropping over 32% and rev. For AYTU investors, management has guided toward an achievable goal, which is to place an estimated 200 MiOXSYS® systems worldwide by the end of 2020. 's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time. 45, but opened at $1. The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Events & Presentations, at aytubio. However, it looks like Sabby does their due diligence. (KMPH)’s share price decreased by -7. It will be interesting to see who the "Single healthcare dedicated institutional investor" is that bought the entire $9M offering. The shares outstanding are 65. Aytu Bioscience Company Profile. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. A company's changing earnings picture is at the core of the Zacks rating. The stock had previously closed at $1. If you have additional questions, please call Investor Relations on 212-492- 1110. The daily trading volume for Aytu BioScience Inc. 27 institutions hold shares in Aytu BioScience Inc. After selling 95,269 shares in the last quarter, the firm now controls 0 shares of Aytu BioScience Inc. 4 thousand shares of Aytu BioScience Inc. Press Release – New York, NY – March 6, 2018 – Sichenzia Ross Ference Kesner LLP announced today that it has represented AYTU Bioscience, Inc. Common Stock (AYTU) at Nasdaq. The company markets ProstaScint (capromab pendetide),. Apr-22-20 08:25AM : Top Oil and Gas Penny Stocks for Q2 2020 Investopedia: 06:00AM : Clean Energy Launches Online Tool to Calculate Costs of Switching from Diesel to Natural Gas V. (NASDAQ:AYTU) over the last session is 7. ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. Institutional investors and hedge funds own 30. (AYTU) Top Institutional Holders. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of an aggregate 12,539,187 shares of Aytu's common. The COVID-19 IgG/IgM is a rapid test intended for the presumptive qualitative detection of IgG/IgM antibodies from the 2019-nCoV in blood samples from individuals with signs and symptoms of infection who are suspected of Sars Cov-2. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 4,450,000 shares of the Company’s common. Detailed company description & address for Canopy Growth Corp. 56, with a volume of 9,828,269 shares traded. 29 institutions hold shares in Aytu BioScience Inc. 38% of Nektar Therapeutics worth $14,530,000 as of its most recent SEC filing. Lululemon apologises after staffer offends with 'bat fried rice' T-shirt. The institutional investor owned 25,369 shares of the company’s stock after buying an additional 20,465 shares during the quarter. ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. The company just reported its first major institutional investor putting up $200K at a big premium of. On March 19, 2020, Aytu BioScience, Inc. Welcome! Log into your account. For more information, please visit www. (NASDAQ: AYTU) and certain of its. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. 97 percent to ratify at $9. 59M, and float is at 54. ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. Aytu and Innovus Shareholder Meetings to Approve Merger Scheduled for February 13, 2020. 15 apiece with an unnamed healthcare-focused. January 13, Aytu BioScience Obtains CE Marking for Company's MiOXSYS™ System for Male Infertility. Nächsten Hauptversammlungstermine On July 21,2018 23. 0 million of, (i) shares of the Company's Series F Convertible (the "Preferred Stock") which are. Aytu Bioscience Inc (NASDAQ:AYTU) shares gapped up before the market opened on Tuesday. American Premium Water Corporation , a company focused on businesses in the health, beauty and biotech sectors, as well as on harnessing the powers of hydrogen and nanotechnologies paired with CBD to treat health disorders and enhance the quality of life, recently announced an additional financing agreement with an institutional investor at the. 0 million in shares of the Company’s common stock over a 36-month period. Aytu BioScience is pursuing an emergency use authorization with the FDA for the COVID-19 IgG/IgM test. Following these latest developments, around 1. TMX Broadcast Centre The TMX Broadcast Centre is the backdrop used each business day by the media to interview leading figures in the world of finance. 49% in the first quarter, owning 6 million shares of AYTU stocks, with the value of $9 million after the purchase of an additional. January 14, 2020. 5% in the 1st quarter, HoldingsChannel reports. Securities products and services offered to self-directed investors through ST Invest, LLC. Virtu Financial LLC owned approximately 0. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. Aytu BioScience, Inc. (AYTU), with 1. 73% of the company’s shares. On October 11, 2019, Aytu BioScience, Inc. 5% down to 8. 4 thousand shares of Aytu BioScience Inc. 60% of ProPetro Holding Corp. The stock had previously closed at $1. (NASDAQ: AYTU) in a $12 million public offering of Class A Units, comprising common stock and warrants and Class B Units comprising Series B Preferred Stock and Warrants. It has a market capitalization of US$31m, which means it wouldn’t have the attention of many institutional investors. 31, 2017 /PRNewswire/ -- Aytu BioScience, Inc. Aytu BioScience Inc. 00% of the company's stock. 49% in the first quarter, owning 6 million shares of AYTU stocks, with the value of $9 million after the purchase of an additional. The shares outstanding are 56. 40 respectively. It will be interesting to see who the "Single healthcare dedicated institutional investor" is that bought the entire $9M offering. 39 as of December 31, 2018 caused the valuation of the warrant liability to decrease resulting in a derivative gain during the 2018 period. It appears that more than several institutional investors and hedge funds decided to increase stakes in AYTU in the recent period. bought approximately 15. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) — Block & Leviton LLP (www. 's portfolio, making the stock its 14th largest […]. 5% down to 8. 60% of ProPetro Holding Corp. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of Aytu BioScience, Inc. (KMPH)’s share price decreased by -7. Positions in Aytu BioScience Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of an aggregate 16,000,000 shares of Aytu's common. Contact for Investors: James Carbonara. ST Invest is a wholly owned subsidiary of StockTwits, Inc. [NASDAQ:AYTU] by around 2,945,240 shares. In the most recent purchasing and selling session, KemPharm Inc. 80% of the company’s stock. (NASDAQ:AYTU) has 26 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Company insiders that own Aytu Bioscience stock include Armistice Capital Master Fund, David A Green and Joshua R Disbrow. This shows that Aytu Bioscience is outperforming its peers so far this year. Investors who purchased Aytu shares should contact Block & Leviton for a free case evaluation. Aytu BioScience Inc. The institutional investor bought 6. 13D Filing on AYTU (As of the date hereof, Currently, the Company has one well-known institutional investor (from most recent SEC filing) which is Armistice Capital. Aytu Bioscience Inc (NASDAQ:AYTU) shares gapped up before the market opened on Tuesday. Securities products and services offered to self-directed investors through ST Invest, LLC. In addition to Finland, where Icebreaker claims to be the most active institutional investor by number of deals, the. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the purchase and sale of 7,826,087 shares of Aytu's common stock. 44M shares held by insiders accounting for 6. 10 stocks we like better than AT&T When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. 15 per share, in a registered direct offering. The Company will have the right, in its sole discretion, to sell to Lincoln Park up to $25. 0 million shares of the stock in a transaction took place on 3/12/2020. An institutional investor recently bought a new position in Aytu Bioscience stock. 08%), BlackRock Inc. That is how Sabby Capital LLC now has an increase position in AYTU by 55,337. (NASDAQ:AYTU) has 26 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). 42% of the company's stock. 24% while institutional investors hold 12. AYTU Should be A Standout. 29 institutions hold shares in Aytu BioScience Inc. 5 with a mean TP of 3. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. (NASDAQ: AYTU) and certain of its. 04 million shares. 36M, and float is at 54. 42% of the stock is currently owned by hedge funds and other institutional investors. 18 percent to ratify at $1. 37M shares. (AYTU) CEO Joshua Disbrow on Q1 2020 Results - Earnings Call Transcript | Seeking Alpha. ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. On March 10, 2020, Aytu reported that it reached a license agreement for the exclusive distribution of a point-of-care rapid test for certain COVID-19 antibodies in the U. Aytu BioScience, Inc. 6 billion in the largest initial public offering (IPO) on record. (OTCQB: "WIZP"), a clinical stage Israel based U. com, for 90 days. What are institutional investors and what other kinds of investors are there. Positions in Aytu BioScience Inc. (NASDAQ:AYTU) over the last session is 7. ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. Vystar Corp. A total of 19,520,000. 2019-11-15 seekingalpha. The shares outstanding are 60. [NASDAQ:AYTU] by around 2,945,240 shares. 5 with a mean TP of 3. Commenting on the second quarter of 2020, Josh Disbrow, Chief Executive Officer of Aytu BioScience, stated, "Revenue for the three months ended December. 70% of the company’s stock. Thank you for your interest in W. 55M with Short Float at 5. 44M shares held by insiders accounting for 6. 73% of the company’s shares. Virtu Financial LLC owned about 0. 34, with a volume of 5,954,324 shares traded. [NASDAQ:AYTU] by around 2,945,240 shares. That is how Sabby Capital LLC now has an increase position in AYTU by 55,337. Visualisez les marques concurrentes de RANGE ROVER en 1 clic. In the chart below below, we can see that institutions don’t own many shares in the company. ValuEngine upgraded shares of Aytu Bioscience (NASDAQ:AYTU) from a hold rating to a buy rating in a research report sent to investors on Monday morning, ValuEngine reports. Aytu BioScience, Inc. Aytu Announces $9. Clients of the firm include a global institutional investor base domiciled in North America, Europe and Asia. These institutions hold a total of 695,204 shares. 34, with a volume of 5,954,324 shares traded. The shares outstanding are 56. The shares outstanding are 60. Aytu is a specialty pharmaceutical company focused on global commercialization of products addressing a variety of medical needs. In the most recent purchasing and selling session, Lowe’s Companies Inc. Duration: 39 minutes. pursuant to this prospectus supplement and accompanying prospectus to several institutional investors. 15 per share, in a registered direct offering priced at-the-market under Nasdaq rules. [NASDAQ:AYTU] by around 2,945,240 shares. Aytu BioScience, Inc. A sum of 15831692 shares traded at recent session and its average exchanging volume remained at 16. The stock had previously closed at $1. StockHouse. 77M, and float is at 56. bought approximately 15. 38% of Nektar Therapeutics worth $14,530,000 as of its most recent SEC filing. Zacks Investment Research raised […]. Target Price of the company Aytu BioScience, Inc. 00% while insider ownership was 1. 42% of the company’s stock. To break things down more, AYTU belongs to the Medical - Biomedical and Genetics industry, a group that includes 385 individual companies and currently sits at #41 in the Zacks Industry Rank. Pursuant to the Aytu Purchase Agreement, Aytu assumed sales returns of the Pediatric Portfolio made after the closing date of November 1, 2019 and primarily relating to sales prior to November 1, 2019 only to the extent such post-Closing sales returns exceed $2. 0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country's financial markets. In depth view into AYTU (Aytu BioScience) stock including the latest price, news, dividend history, earnings information and financials. 59M, and float is at 54. 71% compared to the previous one. That is how Sabby Capital LLC now has an increase position in AYTU by 55,337. The analyst consensus points to a rating of ‘Strong_Buy’. KS: KR MOTORS. In the most recent purchasing and selling session, Lowe’s Companies Inc. AYTU Stock Message Board: An institutional investor is buying 9 million share. 55M with Short Float at 12. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) — Block & Leviton LLP (www. ENGLEWOOD, CO / ACCESSWIRE / March 12, 2020 / Aytu BioScience, Inc. [NASDAQ:AYTU] by around 2,945,240 shares. Aytu BioScience, Inc today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of an aggregate 16,000,000. bought approximately 15. That concludes today's call. Axa's holdings in The Coca-Cola were worth $115,156,000 at the end of the most recent reporting period. boosted its holdings in Aytu Bioscience Inc (NASDAQ:AYTU) by 9. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 13 institutional holders increased their position in Aytu BioScience Inc. 14% of Aytu Bioscience at the end of the most recent quarter. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. (the "Company") entered into Securities Purchase Agreements (the "Purchase Agreement") with two institutional accredited investors (the "Investors") providing for the issuance and sale by the Company (the "Offering") of $10. XpresSpa would. The shares outstanding are 65. 0 million shares of the stock in a transaction took place on 3/12/2020. The shares outstanding are 60. com reports. Several analysts have recently issued reports on the company. KS: KR MOTORS. 14% of Aytu Bioscience at the end of the most recent quarter. (AYTU) and certain of its officers for potential securities fraud. In the most recent purchasing and selling session, Lowe’s Companies Inc. The purchase price of each Pre-Funded Warrant will equal the price per share at which the common shares are being sold in this offering, minus $0. An institutional investor recently bought a new position in Aytu Bioscience stock. A total of 19,520,000. In the most recent purchasing and selling session, KemPharm Inc. Following these latest developments, around 1. (NASDAQ: AYTU) and certain.